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Allogeneic hematopoietic stem cell transplantation (HSCT) is used for the treatment of 
selected hematological malignancies. Its curative potential is based on two very different 
mechanisms, involving the conditioning regimen and the graft-versus-host reactions, 
respectively. The high-dose chemo-radiotherapy conditioning regimen is aimed at destroying 
tumor cells, ablating the host immune system (to prevent rejection) and eliminating the host bone 
marrow (to “make space” for donor stem cells). However, the definitive eradication of tumor 
cells is also largely mediated by an immune-mediated destruction of malignant cells by donor 
lymphocytes termed graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect. However, 
because of its toxicity, conventional allogeneic HSCT is restricted to younger (< 55 years) and 
fitter patients. These observations led several groups to set up new (less toxic) transplant 
protocols based on a two step approach : first the use of immunosuppressive (but 
nonmyeloablative) conditioning regimens providing sufficient immunosuppression to achieve 
engraftment of allogeneic hematopoietic stem cells and, in a second step, destruction of 
malignant cells by the GVL effect. These transplants are called nonmyeloablative HSCT or 
reduced-conditioning HSCT or minitransplants. Preliminary results show that minitransplants are 
feasible with a relatively low transplant-related mortality (TRM) even in patients up to 70 years. 
In addition, strong anti-tumor responses are observed in several hematological malignancies as 
well as in some patients with renal cell carcinoma. As the benefits of minitransplants over 
alternative forms of treatment remain to be demonstrated, this strategy should be restricted to 





 The curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) is 
mediated not only by the eradication of malignant cells by high-dose chemotherapy (and total 
body irradiation), but also by an immune-mediated graft-versus-leukemia (GVL) or graft-versus-
tumor (GVT) effect (1,2). The power of the GVL effect and its apparent mediation by donor 
lymphocytes led several groups to infuse donor lymphocytes (DLI) in patients with relapsed 
leukemia after HSCT (3,4). The induction of durable remissions by DLI demonstrated that the 
GVL effect is capable of eradicating hematological malignancies even in the absence of 
chemotherapy. This prompted the introduction of new protocols based on the development of a 
GVL reaction after low-dose (less toxic) nonmyeloablative preparative regimens providing 
sufficient immunosuppression to achieve engraftment of allogeneic hematopoietic stem cells 
(figure 1).  
 
THE GVL EFFECT 
 The existence of a GVL effect in humans was first demonstrated by the Seattle’s group 
that evidenced a reduced relapse rate in patients with acute (1) and/or chronic (2) graft-versus-
host disease (GVHD). This was confirmed by others groups that observed an increased risk of 
relapse after T cell-depleted (TCD) allogeneic HSCT as well as after syngeneic HSCT (5). The 
GVL effect was also demonstrated by the evolution of minimal residual disease post-transplant, 
which often ceases to be detectable only 6 to 12 months after HSCT and by the occurrence of 
GVL activity with or without GVHD after cessation of GVHD prophylaxis for post-transplant 
relapse (6).  
This led several groups to infuse donor lymphocytes (DLI) in patients with relapsed 
leukemia after HSCT (3,4). DLI induce a complete remission in about 65 % of the cases in 
chronic myelogenous leukemia (CML) and in 20 to 30 % of the cases in acute myelogenous 
leukemia (AML) or myelodysplasic syndromes (MDS) (3,4). Some patients with acute 
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), 
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non-Hodgkin’s lymphoma (NHL) as well as multiple myeloma (MM) have also responded to 
DLI or discontinuation of immunosuppressive therapy (3,4). A GVT effect has also been 
demonstrated in breast cancer (7) and in renal cell carcinoma (RCC) (8), and possibly in ovarian 
(9) and non-small cell lung (10) carcinomas.  
However, the GVL effect mediated by DLI needs time : the median time to achieve a 
cytogenetic remission was 85 (range 28 to 241) days for patients with CML (the time to achieve 
molecular remission can be prolonged) and 34 (range 16 to 99) days for patients with AML (11). 
Complications of DLI include acute and chronic GVHD and transient marrow aplasia. It is 
possible to reduce the risk of GVHD without impairing the GVL effect by CD8 depletion of DLI 
(12) or by starting with a low dose of T cells and increasing the dose in a stepwise fashion in 
case of no response (13).  
 
ROLES OF THE CONDITIONING REGIMEN 
 
Allogeneic HSCT was first considered to deliver supralethal doses of chemotherapy and 
total body irradiation to tumor cells. The beneficial effect of high doses of chemo-radiotherapy is 
illustrated by the decreased incidence of disease relapse after autologous HSCT compared to 
conventional therapy alone in several hematologic malignancies (14,15) (figure 2). However, a 
large part of the efficacy of allogeneic HSCT is mediated by immune-based GVL or GVT effects 
(figure 2). 
Immature progenitor cells occupy defined niches within the marrow stroma in order to 
obtain the necessary support for proliferation and differentiation. To allow access for donor cells 
to these niches, it was commonly believed that host stem cells must be eradicated by the 
conditioning regimen. However, Storb et al recently demonstrated that the graft itself, most 
likely through subclinical GVH reactions, is capable to create these marrow spaces in the 
absence of both chemotherapy and bone marrow irradiation (16).  
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 It is necessary to abolish host defense prior to transplantation to avoid immune- mediated 
graft rejection caused by alloreactive cytotoxic host lymphocytes or by HLA-specific antibodies. 
It was commonly believed that the conditioning regimen was critical for ensuring engraftment. 
However, donor T lymphocytes (and particularly donor CD8 lymphocytes) are also strongly 
implicated in the destruction of the host immune system (17). Therefore, TCD of the graft as a 
method to prevent GVHD may have deleterious effects on engraftment (18). Recently, the 
Seattle’s group demonstrated that optimizing postgrafting immunosuppression can also control 
the host-versus-graft reaction (19). Thus, contrarily to TCD of the graft that prevents GVHD but 
increases the risk of graft rejection, optimal postgrafting immunosuppression reduces the 
incidence of both GVHD and rejection.  
 
NONMYELOABLATIVE CONDITIONING REGIMENS 
Because of its toxicity, conventional allogeneic HSCT is restricted to younger patients 
(<55 years for allograft procedures with HLA-identical siblings and < 50 years for unrelated 
donor transplants) without significant organ impairment. Unfortunately, the majority of 
malignancies potentially cured by allogeneic HSCT and for which a GVL effect has been 
demonstrated are more frequent in older patients. Thus, it may be important to develop less toxic 
approaches to allografting that can also be extended to older patients or patients with pre-existing 
organ impairment (figure 1).  
In 1997, Giralt et al. (20) reported the engraftment of HLA-identical allogeneic HSC after 
nonmyeloablative chemotherapy based on purine analogs. The rationale for using purine analogs 
(fludarabine or 2-CDA) was their capacity to inhibit the mixed lymphocyte reaction in vitro and 
to produce lymphopenia and substantial immunosuppression in vivo. Other pilot trials by the 
same group confirmed these preliminary results and achieved durable engraftment and 
remissions in some patients with myeloid as well as lymphoid malignancies, with a relatively 
low TRM (21,22). The Jerusalem’s group developed another nonmyeloablative purine analog-
based protocol combining fludarabine, ATG and low-dose oral busulfan (23). This allowed 
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achieving engraftment and full donor chimerism in the majority of the patients with a low TRM. 
However, it should be emphasized that many patients included in this study would be considered 
eligible for conventional allogeneic HSCT. The feasibility of fludarabine-based 
nonmyeloablative transplant protocols has also been confirmed more recently by several others 
groups (24-26).  
In an elegant canine allogeneic transplant model, the Seattle’s group demonstrated that 
stable mixed chimerism could be achieved using pre-transplant low-dose TBI combined with 
post-grafting immunosuppression with a combination of Cyclosporine A (CsA) and 
mycophenolate mofetyl (MMF) and that post-grafting immunosuppression can serve to control 
both HVG and GVH reactions (19). Complete chimerism was achieved through DLI. Initial 
experience in humans showed the feasibility and safety of this approach (27). Moreover, major 
disease responses were observed in more than 70% of the patients who had measurable disease 
pretransplant and achieved sustained engraftment (27).  
Finally, the Boston’s group demonstrated in a murine model (28) and then in humans that 
mixed chimerism could be induced in HLA-matched (29) or 2 or 3 loci-mismatched (30) 
allogeneic HSCT by a nonmyeloablative conditioning regimen combining cyclophosphamide, 
thymic irradiation and ATG. 
 
MIXED HEMATOPOIETIC CHIMERISM  
 Minitransplants usually result initially in mixed hematopoietic chimerism (MC) that can 
be defined as the presence of 1-95% hematopoietic cells of donor origin (figure 1). This state is 
characterized by mutual donor-host tolerance (and thus control of both GVH and host-versus-
graft (HVG) reactions) while immune responses against other antigens remain normal. The 
mechanisms involved include central thymic deletion of both donor- and host-reactive T-cells 
(because both donor and host dendritic cells are present in the thymus of mixed chimera) and 
peripheral tolerance due to suppressor T-cells (31).  
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For the treatment of hematologic malignancies, mixed donor chimerism is not expected to 
be always curative. It is now well demonstrated that MC is associated with relapse in patients 
with diseases such as CML. For those patients with hematologic malignancies, MC can thus be 
converted to full donor chimerism (FC) by DLI (figure 1). 
 The assessment of hematopoietic chimerism requires more sensitive techniques than 
conventional cytogenetic analyses because of the availability of only small numbers of dividing 
cells. The most current techniques are fluorescent in situ hybridization (FISH) with X- and Y- 
specific probes in case of sex-mismatched transplant and polymerase chain reaction-based assays 
of polymorphic mini- or micro-satellite markers in case of sex-matched transplant. Other 
techniques based on restriction fragment length polymorphism (RFLP) are also used.  
The evolution of myeloid and lymphoid chimerism after non-myeloablative HSCT may 
be discordant. Achievement of full donor T-cell chimerism is associated with disease regression 
(24). Moreover, the Seattle’s group recently showed that the level of T-cell chimerism on day 28 
predicted for both graft failure and acute GVHD (27), underlying the importance of lineage-
specific chimerism analysis.  
 
ENGRAFTMENT AND TOXICITY AFTER MINITRANSPLANTS 
 The engraftment rate is related to the intensity of the conditioning as well as the type of 
transplant. Generally, more intensive conditioning regimens resulted in higher engraftment rates 
: graft failure rates ranged from 0% to 20% of the cases in the Jerusalem’s and in the Seattle’s 
studies, respectively (23,27). Moreover, the immune status of the recipient also appeared to be 
important for engraftment. For example, a high incidence of graft rejection was observed by the 
Seattle’s group in previously untreated CML patients, inducing them to add fludarabine in their 
“TBI only” protocol for such patients.  
 Generally, the conditioning regimens used in the setting of minitransplants are well 
tolerated, inducing little or no grade 3-4 toxicity, even in patients older than 65 years or with 
concomitant comorbidities. However, there are important discrepancies among the different 
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studies, due to the relative intensity of the regimen used, the age of the patients as well as the 
type of transplant (sibling versus unrelated, HLA-identical versus mismatch). The 200-day 
transplant-related mortality (TRM) varied from 4% in the Seattle study (27) (using low dose TBI 
alone as conditioning regimen in HLA-identical sibling transplants) to 37% in the Houston’s 
study (22) (using melphalan and purine analog-containing preparative regimens in related or 
unrelated graft recipients ineligible for conventional transplants). Age and disease status at 
transplantation remain important prognostic factors for TRM. 
 In both animal and human studies, the use of less severe conditioning as well as the initial 
presence of host hematopoietic cells decrease the severity of acute GVHD. These observations 
predict that acute GVHD may be limited after minitransplants because of the low intensity of the 
conditioning and the high incidence of mixed chimerism achieved. Indeed, preliminary data 
suggest that acute GVHD is relatively mild and generally controllable after minitransplants (27). 
Moreover, acute GVHD is usually delayed and occurs after patients have recovered from 
conditioning-related toxicities (24,27). However, there are relatively large discrepancies among 
the different studies. This variability probably relates to differences in the source of stem cells 
(bone marrow versus PBSC), type of transplant (related versus unrelated), GVHD prophylaxis, 
use of ATG as well as age of the patient. In fact, acute GVHD is still the leading cause of non-
relapse mortality. Additional DLI are significantly associated with increased risks of acute 
GVHD (29). However, the time of infusion as well as the dose of lymphocytes given play a 
major role. 
 Because of the short follow-up, the incidence and severity of chronic GVHD are still 
uncertain. However, preliminary trials reported the occurrence of severe chronic GVHD in some 
cases (21).  Moreover, despite such short follow-up, the risk of chronic GVHD was already 74% 




 Although data are too early to definitively assess antitumor effects, preliminary results 
clearly demonstrate the occurrence of major disease responses in patients with hematological 
malignancies as well as some solid tumors. 
 
CLL and lymphoma 
 Durable complete responses were observed in several patients with refractory non-
Hodgkin’s lymphoma (NHL), Hodgkin’s disease (HD) or CLL (21,30). The Boston’s group 
reported the evolution of 16 patients treated with minitransplant after a conditioning regimen 
combining cyclophosphamide, ATG and thymic irradiation for primary refractory or relapsing 
resistant NHL, HD or CLL. Complete responses were observed in 7/16 patients (4/11 patients 
with NHL, 2/3 patients with HD and 1/2 patients with CLL). Similarly, the Jerusalem’s group 
reported on a group of 23 heavily treated high-risk malignant lymphomas (32). There were 12 
patients with resistant disease and 11 with partial response, with 5 having failed a previous 
autologous transplant. Ten of the 23 patients were alive in CR 15 to 37 months after the 
transplant and the 3-year probability of disease-free survival was 40%. Kottaridis et al. reported 
on 14 patients with HD or NHL in partial remission (n=8) or with refractory disease (n=6) (24). 
The conditioning regimen consisted in fludarabine, melphalan and CAMPATH-1H. Five out of 
the 14 patients experienced a complete response and stabilization occurred in 7 others patients.  
 
CML 
Complete cytogenetic or molecular remissions were obtained in more than 75% of CML 
patients transplanted in chronic phase (22,24,25,27,33). Moreover, some patients with more 




Durable (> 1 year) partial and complete responses were also observed in some patients 
with multiple myeloma (25,27,34). Badros et al. (34) studied 16 relapsing multiple myeloma 
patients (10 in refractory relapse, 4 with partial response and 2 with near CR) receiving a 
minitransplant after conditioning with melphalan 100 mg/m2. After a median follow-up of 1 
year, 5 patients achieved and sustained CR, 3 near CR and 4 partial response (PR). Two patients 
died of progressive disease and 3 died of GVHD without active disease.  
 
AML, ALL and MDS 
Storb recently reported the results of 17 AML patients treated with related minitransplant 
after conditioning with 2 Gy TBI + fludarabine (90 mg/m2) (35). Eight of 10 patients grafted in 
CR remained in CR after 5-18 months. Moreover, 2/3 patients with primary refractory disease 
were in remission at more than 20 months. Prolonged remissions in refractory AML patients 
were also reported by other groups (22,33).  
 
Solid tumors  
 In patients with solid tumors, responses were partial and transient in patients with breast 
cancer or melanoma, whereas some patients with RCC achieved durable complete responses 
(8,24). Childs et al. recently reported the evolution of 19 patients treated with minitransplant 
after conditioning with fludarabine and cyclophosphamide for metastatic RCC (8). Ten of the 19 
patients enjoyed major responses, including 3 patients with sustained (> 20 months) complete 
response. These responses occurred 3-6 months after the transplant and usually after 
cyclosporine discontinuation. Acute GVHD was associated with disease response but, 
interestingly, one patient had a complete response in the absence of acute GVHD. 
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MINITRANSPLANT AFTER A PREVIOUS CONVENTIONAL TRANSPLANT 
 Treatment options for patients who relapse or develop secondary malignancies after 
autologous or allogeneic HCT are limited. In these patients, results of a second allogeneic HSCT 
are generally poor, primarily because of a high rate of TRM. Recently, the Jerusalem’s group 
studied the feasibility of a second allogeneic HSCT after a nonmyeloablative conditioning 
regimen (36). Among the 12 patients included, only one died of procedure-related complications, 
suggesting that low-intensity regimens significantly reduce TRM associated with second 
transplants. Moreover, the actuarial disease-free survival at 34 months was 50%. These findings 
were confirmed by Kottaridis et al. who reported a 14% TRM associated with an allogeneic 
minitransplant for disease relapses occurring after standard autologous or allogeneic HSCT (25). 
We also reported a low incidence of transplant-related mortality in patients receiving a 
minitransplant after relapsing after a conventional autologous transplantation (37).  
 For patients with high tumor burden, the Genoa’s group studied the feasibility of 
conventional autologous HSCT followed by a minitransplant 1 to 3 months later (26) (figure 2). 
The rationale for high-dose therapy followed by autologous HSCT was debulking and the 
rationale for minitransplant was to induce immune-mediated anti-tumor effects. The rationale for 
separating high-dose therapy from allogeneic transplantation was to reduce the TRM and the risk 
of acute GVHD (see above). Preliminary results evidenced the feasibility of this approach with a 
low TRM (26).  
  
T CELL DEPLETION OF THE GRAFT 
 It is now well demonstrated that a conditioning regimen-related cytokine storm plays a 
major role in the pathogenesis of GVHD. Moreover, in the minitransplant setting, it is well 
demonstrated that donor lymphocytes given several weeks after the transplant in mixed chimera 
induce significantly less GVHD than a similar dose of donor T-cells given together with the 
transplant, without reducing their anti-tumor efficacy (28). We have recently reported that 
transplantation of CD34-selected allogeneic PBSC after a myeloablative preparative regimen 
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followed by pre-emptive CD8-depleted DLI significantly decreases the incidence of acute and 
severe chronic GVHD as compared with unmanipulated BMT (38). We also investigated the 
feasibility and efficacy of minitransplants with CD8-depleted or CD34-selected PBSC followed 
by pre-emptive CD8-depleted DLI given in incremental doses on days 40 and 80 (depleted 
group). None of the ten patients included in the depleted group versus 3/4 recipients of 
unmanipulated PBSC and DLI experienced grade II-IV acute GVHD. Most of the patients 
included in the depleted group were mixed chimera on day 30 but became full donor chimera 
after CD8-depleted DLI (37).    
 Kottaridis et al. (25) recently investigated a novel nonmyeloablative conditioning 
regimen consisting in CAMPATH-1H, fludarabine (150 mg/m2) and melphalan (140 mg/m2). 
They observed a high engraftment rate (> 97%) but most of the patients analyzed were mixed 
chimera. The incidence of GVHD was exceptionally low (5% of grade II-IV acute GVHD). The 
authors explain this observation by the use of in-vivo CAMPATH-1H (achieving in vivo T-cell 
depletion of the graft because of its prolonged half-life in humans) and by the high incidence of 
mixed chimerism (known to reduce the incidence and severity of GVHD). However, as mixed 
chimerism may diminish the GVL effect seen in the allograft setting, longer follow-up is needed 
to clarify if this approach respects the GVL effect.    
 
CONCLUSION 
In conclusion, minitransplants are feasible and can lead to molecular responses. This 
transplant strategy offers several advantages over conventional HSCT: [1] TRM is reduced; [2] 
acute GVHD could be less frequent and less severe than after myeloablative HSCT; [3] 
minitransplant are possible in patients older than 55 or with concomitant comorbidities. Further 
clinical trials are needed to define more effective strategies to separate GVL effects from GVHD 
and to compare the relative efficacy of this approach to conventional treatment (39).  
 The potential indications for a minitransplant include the same disease indications as for a 
standard transplant but in patients unfit for a myeloablative conditioning regimen because of age 
 13
(> 50-55 to 70 yrs) or poor clinical condition (infection, organ failure). It is not unlikely that 
minitransplants could replace standard transplants even in young fitter patients for diseases such 
as CML. In addition, minitransplants may be used in diseases where GVT effects are more 
important than high-dose chemotherapy, such as renal cell carcinoma. In the future, the potential 
of minitransplants to replace a diseased hematopoietic or immune system may also be exploited 
to cure non-malignant hematological disorders (such as aplastic anemia, thalassemia, sickle cell 
disease or SCID) or autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis or 
sclerodermia). Finally, combination of HSC and solid organ transplants from the same donor 
may provide definitive tolerance toward the transplanted organ and eliminate the need for 
prolonged immunosuppression.  
As the benefits of minitransplants over alternative forms of treatment remain to be 
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LEGEND TO THE FIGURES 
 
 
Figure 1 : Schedule of minitransplant. Pre-transplant recipient immunosuppression is carried out 
with either low-dose chemotherapy or chemo-radiotherapy. Patients receive donor HSC on day 
0. Post-grafting immunosuppression is carried out with cyclosporine A with or without MMF or 
MTX. DLI are given 30-100 days after the transplant in case of mixed chimerism and/or residual 
disease to obtain full donor chimerism as well as eradication of tumor cells.        
            Cell of host origin.          Cell of donor origin.              Host tumor cell. 
 
Figure 2 : Comparison of various approaches to allogeneic HSCT. 
A. Conventional allogeneic transplantation. After a complete remission (CR) is achieved 
through standard chemotherapy, conditioning with massive doses of chemo-radiotherapy 
further reduces residual disease that is finally eradicated by the GVL effect. 
B. Minitransplant. After low-intensity conditioning that has little impact on the tumor, 
transplantation of allogeneic stem cells and further DLI are responsible for the eradication of 
the tumor. 
C. Conventional autologous transplantation followed by a mini-allotransplant. After initial CR, 
high-dose conditioning (with autologous HSCT rescue) further reduces residual disease. 
Then, a minitransplant is carried out. This is the equivalent of performing a standard 
allogeneic transplant in 2 steps, i.e. a first step of chemotherapy intensification (autologous 
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